Hyaluronan-Stabilized Redox-Sensitive Nanoassembly for Chemo-Gene Therapy and Dual T1/T2 MR Imaging in Drug-Resistant Breast Cancer Cells

Rajendrakumar, Santhosh Kalash; Venu, Akhil; Revuri, Vishnu; Thomas, Reju George; Thirunavukkarasu, Guru Karthikeyan; Zhang, Jun; Vijayan, Veena; Choi, Seok‐Yong; Lee, Jae Young; Lee, Yong-Kyu; Jeong, Yong Yeon; Park, Inkyu

doi:10.1021/acs.molpharmaceut.9b00189

Cited by 22 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…168 Disulfide cross-linked polyethylenimine (ssPEI) nanogels were used to carry a DOX-intercalated plasmid encoding Bcl-2 shRNA for killing cells and combating drug resistance, respectively. 169 When exposed to the reductive cytoplasm, ssPEI nanogels rapidly released plasmid DNA and DOX, which promoted the movement of plasmid DNA into the nucleus, leading to subsequent gene expression. After the Bcl-2 gene was successfully silenced in multidrug-resistant tumor cells, the cytotoxicity of Bcl-2 silencing obviously improved the capacity of DOX to kill cells.…”

Section: Molecular Pharmaceuticsmentioning

confidence: 99%

“…Hence, redox-responsive polyethylenimine nanogels are potential candidates for the rapid release of nucleic acids in the cytosol . Disulfide cross-linked polyethylenimine (ssPEI) nanogels were used to carry a DOX-intercalated plasmid encoding Bcl-2 shRNA for killing cells and combating drug resistance, respectively . When exposed to the reductive cytoplasm, ssPEI nanogels rapidly released plasmid DNA and DOX, which promoted the movement of plasmid DNA into the nucleus, leading to subsequent gene expression.…”

Section: Gelling Strategies and Drug Release Based On Internal And Ex...mentioning

confidence: 99%

See 1 more Smart Citation

Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review

et al. 2020

View full text Add to dashboard Cite

As an emerging drug carrier, hydrogels have been widely used for tumor drug delivery. A hydrogel drug carrier can cause less severe side effects than systemic chemotherapy and can achieve sustained delivery of a drug at tumor sites. In addition, hydrogels have excellent biocompatibility and biodegradability and lower toxicity than nanoparticle carriers. Smart hydrogels can respond to stimuli in the environment (e.g., heat, pH, light, and ultrasound), enabling in situ gelation and controlled drug release, which greatly enhance the convenience and efficiency of drug delivery. Here, we summarize the different sizes of hydrogels used for cancer treatment and their related delivery routes, discuss the design strategies for stimuli-responsive hydrogels, and review the research concerning smart hydrogels reported in the past few years.

show abstract

Section: Molecular Pharmaceuticsmentioning

confidence: 99%

Section: Gelling Strategies and Drug Release Based On Internal And Ex...mentioning

confidence: 99%

Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…HART nanoassembly could achieve CD44-mediated intracellular uptake in MCF7 breast cancer cells and redox-responsive drug-gene release. The HART nanoassembly also contained a dual MRI contrast (T1/T2) agent and demonstrated efficacy in vitro [ 258 ]. Qiao et al designed a redox-triggered micelle encapsulating mitoxantrone prodrug for overcoming MDR in breast cancer.…”

Section: Nanomedicine To Overcome Drug Resistance In Breast Cancermentioning

confidence: 99%

Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

Gote

Nookala

Bolla

et al. 2021

IJMS

101

View full text Add to dashboard Cite

Breast cancer, specifically metastatic breast, is a leading cause of morbidity and mortality in women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for cancer relapse is the development of multidrug resistance (MDR) hampering the treatment and prognosis. MDR can occur due to a multitude of molecular events, including increased expression of efflux transporters such as P-gp, BCRP, or MRP1; epithelial to mesenchymal transition; and resistance development in breast cancer stem cells. Excessive dose dumping in chemotherapy can cause intrinsic anti-cancer MDR to appear prior to chemotherapy and after the treatment. Hence, novel targeted nanomedicines encapsulating chemotherapeutics and gene therapy products may assist to overcome cancer drug resistance. Targeted nanomedicines offer innovative strategies to overcome the limitations of conventional chemotherapy while permitting enhanced selectivity to cancer cells. Targeted nanotheranostics permit targeted drug release, precise breast cancer diagnosis, and importantly, the ability to overcome MDR. The article discusses various nanomedicines designed to selectively target breast cancer, triple negative breast cancer, and breast cancer stem cells. In addition, the review discusses recent approaches, including combination nanoparticles (NPs), theranostic NPs, and stimuli sensitive or “smart” NPs. Recent innovations in microRNA NPs and personalized medicine NPs are also discussed. Future perspective research for complex targeted and multi-stage responsive nanomedicines for metastatic breast cancer is discussed.

show abstract

“…[ 144 ] A hybrid Mn 3 O 4 /Fe 3 O 4 nanoparticle was developed to co‐deliver Dox and Bcl2 shRNA to drug‐resistant breast cancer MCF‐ADR. [ 145 ] Interestingly, an NIR‐responsive, hollow gold nanoparticle (HGNP) was developed for sequential release of miRNA and Dox. [ 146 ] This study highlights HGNP's capability for treating both cancer cells and cancer stem cells to reduce the risk of tumor recurrence.…”

Section: Combinatorial Delivery Of Gene–chemo Therapeutics By Inorganmentioning

confidence: 99%

Inorganic Nanomaterial‐Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities

Lin

Revia

Zhang

2020

Adv Funct Materials

View full text Add to dashboard Cite

Cancer is a genetic disease originating from the accumulation of gene mutations in a cellular subpopulation. Although many therapeutic approaches have been developed to treat cancer, recent studies have revealed an irrefutable challenge that tumors evolve defenses against some therapies. Gene therapy may prove to be the ultimate panacea for cancer by correcting the fundamental genetic errors in tumors. The engineering of nanoscale inorganic carriers of cancer therapeutics has shown promising results in the efficacious and safe delivery of nucleic acids to treat oncological diseases in small‐animal models. When these nanocarriers are used for co‐delivery of gene therapeutics along with auxiliary treatments, the synergistic combination of therapies often leads to an amplified health benefit. In this review, an overview of the inorganic nanomaterials developed for combinatorial therapies of gene and other treatment modalities is presented. First, the main principles of using nucleic acids as therapeutics, inorganic nanocarriers for medical applications and delivery of gene/drug payloads are introduced. Next, the utility of recently developed inorganic nanomaterials in different combinations of gene therapy with each of chemo, immune, hyperthermal, and radio therapy is examined. Finally, current challenges in the clinical translation of inorganic nanomaterial‐mediated therapies are presented and outlooks for the field are provided.

show abstract

Hyaluronan-Stabilized Redox-Sensitive Nanoassembly for Chemo-Gene Therapy and Dual T1/T2 MR Imaging in Drug-Resistant Breast Cancer Cells

Cited by 22 publications

References 37 publications

Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review

Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review

Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

Inorganic Nanomaterial‐Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities

Contact Info

Product

Resources

About